Healthcare investor GHO Capital has acquired Quotient Clinical, a Translational Pharmaceutics company
Quotient Clinical’s Translational Pharmaceutics platform takes a pharmaceutical agent through the steps of development from the laboratory to the clinic.
As part of the acquisition GHO Capital will gain Quotient Clinical’s Pharmaceutics platform, which specifically integrates formulation development, real-time GMP manufacturing and clinical testing.
Mark Egerton, chief executive officer of Quotient Clinical, said: “We are delighted to be partnering with GHO Capital for the next phase of our growth.
“We will now work to expand our differentiated service portfolio and extend our operational footprint internationally.”
Mike Mortimer, executive partner and founder at GHO Capital, said: “Outsourced services and contract development and manufacturing is a space that GHO Capital knows extremely well.
“Quotient Clinical has a highly attractive business model which can be scaled and expanded – particularly across Europe and the USA – making this an excellent investment opportunity for our fund.”
Financial details of the transaction remain undisclosed.